Evidence map›Paper›PMID 34168445›Full record

ArticleInternational journal of nanomedicine2021

Curcumin-Loaded Hybrid Nanoparticles: Microchannel-Based Preparation and Antitumor Activity in a Mouse Model.

Weiyong Hong, Ying Gao, Bang Lou, Sanjun Ying, Wenchao Wu, Xugang Ji, Nan Yu, Yunlong Jiao, Haiying Wang, Xuefeng Zhou and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Weiyong HongDepartment of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China.
Ying GaoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Bang LouCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Sanjun YingCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Wenchao WuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Xugang JiCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Nan YuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Yunlong JiaoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Haiying WangDepartment of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China.
Xuefeng ZhouDepartment of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China.
Anqin LiZhejiang Share Bio-Pharm Co., Ltd, Hangzhou, 310019, People's Republic of China.
Fangyuan GuoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.ORCID 0000-0002-5401-1683
Gensheng YangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.ORCID 0000-0002-6905-8484
Zhejiang University of Technology · CNTaizhou Municipal Hospital · CNZhejiang Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo develop microchannel-based preparation of curcumin (Cur)-loaded hybrid nanoparticles using enzyme-targeted peptides and star-shaped polycyclic lipids as carriers, and to accomplish a desirable targeted drug delivery via these nanoparticles, which could improve the bioavailability and antitumor effects of Cur.

methodsThe amphiphilic tri-chaintricarballylic acid-poly (ε-caprolactone)-methoxypolyethylene glycol (Tri-CL-mPEG) and the enzyme-targeted tetra-chain pentaerythritol-poly (ε-caprolactone)-polypeptide (PET-CL-P) were synthesized. The Cur-loaded enzyme-targeted hybrid nano-delivery systems (Cur-P-NPs) were prepared by using the microfluidic continuous granulation technology. The physicochemical properties, release behavior in vitro, and stability of these Cur-P-NPs were investigated. Their cytotoxicity, cellular uptake, anti-proliferative efficacy in vitro, biodistribution, and antitumor effects in vivo were also studied.

resultsThe particle size of the prepared Cur-P-NPs was 146.1 ± 1.940 nm, polydispersity index was 0.175 ± 0.014, zeta potential was 10.1 ± 0.300 mV, encapsulation rate was 74.66 ± 0.671%, and drug loading capacity was 5.38 ± 0.316%. The stability of Cur-P-NPs was adequate, and the in vitro release rate increased with the decrease of the environmental pH. Seven days post incubation, the cumulative release values of Cur were 52.78%, 67.39%, and 98.12% at pH 7.4, pH 6.8 and pH 5.0, respectively. Cur-P-NPs exhibited better cell entry and antiproliferation efficacy against U251 cells than the Cur-solution and Cur-NPs and were safe for use. Cur-P-NPs specifically targeted tumor tissues and inhibited their growth (78.63% tumor growth inhibition rate) with low toxic effects on normal tissues.

conclusionThe enzyme-targeted hybrid nanoparticles prepared in the study clearly have the tumor-targeting ability. Cur-P-NPs can effectively improve the bioavailability of Cur and have potential applications in drug delivery and tumor management.

Indexed as

Lab-On-A-Chip DevicesAnimalsAntineoplastic AgentsBiological AvailabilityCaproatesCell Line, TumorCurcuminDrug CarriersHumansLactonesMiceNanoparticlesNanotechnologyParticle SizePolyethylene GlycolsTissue DistributionAntineoplastic AgentsCaproatescaprolactoneCurcuminDrug CarriersLactonesmonomethoxypolyethylene glycolPolyethylene Glycolsenzyme targetinggrowth inhibitionmouse modelnanoparticle fabrication

Identifiers

PMID34168445
PMCPMC8216735
OpenAlexW3172559619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.